Immunotherapy doubles survival rates for patients with melanoma brain metastases

A new study evaluates data from more than 1,500 cancer programs across the country to determine the effectiveness of checkpoint blockade immunotherapies, finding that these therapies provided significant improvements in overall survival for patients with melanoma brain metastases.

Go to Source

(Visited 2 times, 1 visits today)

Site Footer

Sliding Sidebar